In this randomized, multicenter trial, we evaluated the effectiveness and side effect profile of a modified omeprazole-based triple therapy to cure Helicobacter pylori infection. The control group consisted of patients treated with standard dual therapy comprising omeprazole and amoxicillin. One hundred and fifty-seven H. pylori infected patients with duodenal ulcers were randomly assigned to receive either a combination of omeprazole 10 mg, clarithromycin 250 mg and metronidazole 400 mg (OCM) given three times daily for 10 days (n = 81), or a combination of omeprazole 20 mg and amoxicillin 1 g (OA) given twice daily for 14 days (n = 76). Prior to treatment and after 2 and 6 weeks, gastric biopsies from the antrum and corpus were obtained for histology and H. pylori culture. H. pylori infection was cured in 97.4% after OCM and in 65.8% after OA in the per-protocol analysis (p ! 0.001) (intentionto-treat analysis: 93.4% and 63.2%, respectively). H. pylori was successfully cultured in 122 patients (77%). The overall rate of metronidazole resistance was 19.7% (24/122), no primary resistance to clarithromycin or amoxicillin was found. In the OCM group, all patients infected with metronidazole-sensitive H. pylori strains (n = 51) and those infected with strains of unknown susceptibility to metronidazole (n = 14) were cured (100%), while 77% (10/13) of those harboring metronidazole-resistant strains were cured of the infection (p = 0.36). Side effects leading to premature termination of treatment occurred in 2.5% of the patients in the OCM group and in 1.4% of the OA group. We conclude that combined treatment with omeprazole, clarithromycin and a higher dose of metronidazole is highly effective in curing H. pylori infection, and that this regimen remains very effective in the presence of metronidazoleresistant strains. 
Introduction
It is well recognized that Helicobacter pylori is the principal cause of chronic gastritis and duodenal ulcer disease [1] . In 1994, the National Institute of Health Consensus Development Conferences on H. pylori in peptic ulcer disease recommended antimicrobial therapy for ulcer patients whether on the first presentation of illness or on recurrence [2] . However, in routine practice, cure of the infection has proven to be difficult. Complex regimens such as the combination of bismuth salts, metronidazole and tetracycline although highly effective are limited by poor patient compliance or antimicrobial resistance to nitroimidazoles [3] . Dual therapy comprising omeprazole and amoxicillin (OA) is simple, well tolerated, and cures H. pylori infection in up to 90% depending on the daily dose of omeprazole [4, 5] , however, variable cure rates have been reported [6] [7] [8] . Omeprazole-based triple-therapy regimens consistently cure H. pylori infection in 90% and more [9] [10] [11] [12] , however, few data exist about the efficacy of such a regimen in the presence of metronidazoleresistant H. pylori strains. In this randomized study, we evaluated the effectiveness and tolerability of combined treatment with omeprazole, clarithromycin and metronidazole (OCM) each given three times daily in comparison with standard dual therapy comprising omeprazole 20 mg b.i.d. and amoxicillin 1 g b.i.d. In addition, pre-and posttreatment resistance to the antibiotics in use was determined.
Methods

Study Population
Patients aged 18-80 years with H. pylori-associated duodenal ulcers were included in this randomized, multicenter study. Exclusion criteria were an additional gastric or pyloric ulcer, use of bismuth compounds or antibiotics 4 weeks prior to endoscopy, regular consumption of steroids, NSAIDs or more than 100 mg of acetylsalicylic acid per day, previous ulcer surgery, pregnancy, renal insufficiency, known allergy to those antibiotics used and contraindications of biopsy.
Therapy
Patients were randomly treated with either a combination of omeprazole 10 mg, clarithromycin 250 mg and metronidazole 400 mg (OCM) given three times daily with meals for 10 days, or standard dual therapy comprising omeprazole 20 mg and amoxicillin 1 g (OA) given twice daily with meals for 14 days. The latter regimen was the only approved anti-H. pylori therapy in 1993 when the present study was planned. Drug compliance was assessed by pill count and a diary where patients recorded adverse events.
Endoscopy and Histology
Endoscopic examinations were conducted prior to treatment, after 2 weeks to document ulcer healing and after 6 weeks to determine cure of H. pylori infection. At each endoscopy, 4 biopsy specimens from the antrum and 2 from the corpus were obtained for histologic examination, a number considered to ensure reliable detection of H. pylori [13] . Biopsy specimens were placed in neutral buffered formalin. HE staining was performed to grade gastritis, and WarthinStarry staining to detect and grade mucosal H. pylori colonization according to the Sydney System [14] . Patients who were H. pylorinegative at histology and culture prior to treatment were withdrawn and treated conventionally.
H. pylori Culture and Susceptibility Testing
Two antral biopsy specimens were taken for microbiological examinations. Culture biopsies were transported to the Department of Microbiology, in Portagerm pylori transport medium (BioMé-rieux, Marcy-l'Etoile, France) within 24 h. Immediately after arrival, H. pylori was cultured on Pylori agar (BioMérieux) and WilkinsChalgren agar medium supplemented with 10% horse blood and Skirrow Antibiotic Supplement (Oxoid, Basingstoke, UK). H. pylori was identified by typical gram stain morphology, and by biochemical tests positive for oxidase, catalase and urease. For susceptibility testing, cells were harvested from a 2-to 3-day fresh culture on WilkinsChalgren agar and transferred to 1 ml of brucella broth (Difco, Augsburg, Germany). Inoculum density was adjusted to McFarland 3-4 which represents approximately 0.5 ! 10 9 colony-forming units (CFU)/ml. Motility and morphology were checked by phase contrast microscopy. The suspension was discarded if more than one fourth of rounded organisms or clumped aggregates were detected. A WilkinsChalgren agar plate was flooded and allowed to dry for 5-10 min. One E-test strip (AB Biodisk, Solna, Sweden) was placed on the agar, and the plate was incubated under microaerophilic conditions (11% O 2 , 9% CO 2 , 80% N 2 ) for 2-3 days until sufficient growth was visible. The results were read according to the manufacturer's instructions. Interpretation criteria for clarithromycin were sensitive for MIC values ^0.125 mg/l and resistant for 62 mg/l. The corresponding values for metronidazole were 8 and 32 mg/l, and for amoxicillin 2 and 4 mg/l, respectively.
Definition of H. pylori Status
At baseline examination, patients were considered H. pyloriinfected when either histology or culture was positive. Cure of H. pylori infection was assessed at least 4 weeks after completion of treatment, and was defined as being H. pylori-negative on histology and culture.
Statistical calculations were performed using the statistical software package SPSS/PC+5.0 (SPSS Inc., USA). Rate comparisons were made with the ¯2 test. The study was approved by the Ethics Committee of the University of Munich.
Results
One-hundred fifty-seven DU patients infected with H. pylori were randomized to one of the two treatment groups, 81 to the OCM group, and 76 to the OA group. The overall study population consisted of 101 men and 56 women (age range 26-78 years, mean age 49.6 years). There was no statistically significant difference in the patient characteristics between the OCM and the OA group (table 1) . One patient of the OCM group (1.2%) was lost to follow-up. Side effects leading to premature termination of treatment occurred in 2 of 81 patients (2.5%) in the OCM group (diarrhea), and in 1 of 74 patients (1.4%) in the OA group (p 1 0.5) (allergic skin reaction). In all cases, the side effects were self-limiting after termination of treatment. These 4 patients were therefore excluded from the per-protocol analysis. Minor adverse events were observed in 13 patients (16.7%) and in 9 patients (11.8%) in the respective treatment groups (p 1 0.5), mainly mild diarrhea, taste disturbance, mild nausea, headache. Ulcer healing determined 2 weeks after initiation of treatment was achieved in 81/81 patients in the OCM group, and in 74/76 (97.3%) of the patients in the OA group. The 2 patients without documented ulcer healing were also excluded from the per-protocol analysis. Cure of H. pylori infection was documented in 97.4% of patients (76/78) following treatment with OCM (intention-to-treat analysis 93.4%; 76/81) and in 65.8% of patients (48/73) after OA therapy (intention-to-treat analysis 63.2%; 48/ 76) (p ! 0.001). In 122 of 157 patients, culture for H. pylori was successful (77%). Twenty-four of the available 122 pretreatment H. pylori isolates (19.7%) were resistant to metronidazole (13/64 in the OCM group, and 11/58 in the OA group). In the OCM group, all patients infected with metronidazole-sensitive H. pylori strains (n = 51) and those infected with strains of unknown susceptibility to metronidazole (n = 14) were cured (100%), while 77% (10/13) of those harboring metronidazole-resistant strains were cured of the infection (p = 0.36). In the OA group, 8 of 11 (73%) patients infected with metronidazole-resistant strains were cured of the infection. None of the preand posttreatment isolates were resistant to clarithromycin or amoxicillin (table 2).
Discussion
Although H. pylori is sensitive to a number of antimicrobials and anti-ulcer agents in vitro, curing the infection in vivo has proven to be a difficult task. Multi-drug regimens are generally required to achieve consistent high cure rates. In 1993, Bazzoli et al. [9] introduced a simple and highly effective treatment strategy combining omeprazole with two antibiotics given for 1 week. Subsequent trials using different combinations of antimicrobials were able to confirm those data [10] [11] [12] . In the present study, we demonstrated a high efficacy of more than 95% in curing H. pylori infection with a modified omeprazole-based triple therapy comprising clarithromycin and metronidazole given three times instead of twice daily for 10 days. This finding is in agreement with recently reported studies using standard-dose triple-therapy regimens [15, 16] .
A well-recognized problem of various anti-H. pylori therapy regimens is primary resistance of H. pylori against metronidazole ranging from 11 to 25% in Western countries [17] [18] [19] , and even up to 95% in developing countries [20] . While resistance of H. pylori against metronidazole has been shown to be a fundamental problem for the original standard triple therapy comprising bismuth, tetracycline and metronidazole [3] , the effectiveness of the new omeprazole-based triple-therapy regimens in curing infection with metronidazole-resistant H. pylori isolates has not been investigated thoroughly. In the present study, the overall frequency of metronidazole resistance was close to 20%. However, in the 13 patients of the OCM group who harbored metronidazole-resistant H. pylori isolates, 10 (77%) were cured of the infection suggesting that even in the presence of metronidazole resistance this regimen is still effective, either due to the higher daily dose of metronidazole (3 ! 400 mg) or to the extended length of treatment. More strikingly, all other patients in the OCM group (100%) who were infected with metronidazole-sensitive strains or strains with unknown susceptibility were cured, underlining the excellent efficacy of this regimen.
Clarithromycin is one of the most active compounds (MIC 90 1 0.03 g/ml) among the various antimicrobials and anti-ulcer agents that have been tested in vitro against H. pylori [21, 22] . When used as monotherapy, clarithromycin has the ability to cure H. pylori infection in up to 54% of patients [23] . Today, clarithromycin is an essential compound of triple-therapy regimens comprising omeprazole and metronidazole or amoxicillin [24] . Reported resistance rates of H. pylori against clarithromycin range from 0 to 12% [15, [24] [25] [26] . In our study, primary or acquired resistance of H. pylori against clarithromycin did not occur, again indicating the high suitability of this antimicrobial for anti-H. pylori combination regimens.
Dual therapy with OA has initially shown promising results in curing H. pylori infection, in particular when higher daily doses of omeprazole have been used [4, 5, 27] . However, other investigators failed to reproduce these data [6] [7] [8] , and subsequent studies revealed that this regimen may be sensitive to various, mostly patient-related factors. It has been shown that lack of compliance, short duration of therapy, smoking and pretreatment with omeprazole are independent factors with a negative influence on treatment success, while older age of patients, high-grade gastritis and gastric ulcer are predictors for a higher success rate [28] . In this study, the control group was treated with the standard dosage of omeprazole, 20 mg b.i.d. and amoxicillin 1 g b.i.d., since this regimen was the only approved therapy for treatment of H. pyloriassociated ulcers in 1993 when the present study was planned. We observed a 66% cure rate of H. pylori infection, which is basically in agreement with our own previous data [27] and a recent meta-analysis by van der Hulst et al. [29] . Based on 53 treatment arms, including a total of 2,275 patients using omeprazole given twice daily in combination with amoxicillin for 2 weeks, they found a mean eradication rate of 62%. These findings certainly do not justify the use of this regimen as a first-line treatment, however, dual therapy regimens comprising high-dose omeprazole (e.g., 120 mg/day) might be useful in the future when antimicrobial resistance of H. pylori may become a considerable problem.
Another important finding in this study was the excellent rate of ulcer healing determined 2 weeks after initiation of therapy in both treatment arms (OCM 100%, OA 97.3%). These findings are basically in agreement with a recently published randomized double-blind study by Labenz et al. [30] showing that continuation of antisecretory drug therapy beyond anti-H. pylori therapy may be unnecessary to achieve rapid symptom relief and reliable healing of uncomplicated duodenal ulcers. In conclusion, combined treatment with OMC for the cure of H. pylori infection in duodenal ulcer patients is significantly more effective than standard dual therapy with OA. Even in the presence of metronidazole-resistant H. pylori isolates is this modified omeprazole-based triple-therapy regimen very effective, most likely due to the higher daily dose of metronidazole.
